<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03183102</url>
  </required_header>
  <id_info>
    <org_study_id>16-6978H</org_study_id>
    <nct_id>NCT03183102</nct_id>
  </id_info>
  <brief_title>The Role of the Gut Microbiota in Estrogen Metabolism and Dietary Flax as a Potential Modulator.</brief_title>
  <official_title>The Role of the Gut Microbiota in Estrogen Metabolism and Dietary Flax as a Potential Modulator.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Colorado State University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Colorado State University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this pilot study is to determine if suppressing estrogen in premenopausal
      women results in changes in gut microbiota and if dietary flaxseed modulates these changes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This pilot study will begin to address whether gut microbiota change with estrogen
      suppression. Specifically, the investigators will test whether gut microbial diversity and
      abundance change in response to estrogen suppression and consumption of dietary flaxseed. To
      test this possibility the investigators will recruit premenopausal women (age 20-40 years
      old)and collect fecal samples before and after 1 month of estrogen suppression with GnRH
      agonist. The investigators will analyze the gut microbiota in response to estrogen loss and
      whether this differs with the consumption of flaxseed.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2017</start_date>
  <completion_date type="Anticipated">June 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Biological samples will be masked for endpoint analysis</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in gut microbiota diversity</measure>
    <time_frame>At baseline (day 0) and 30 days after estrogen suppression, with and without dietary flaxseed 30 days before estrogen suppression and during the 30 days of estrogen suppression</time_frame>
    <description>16s rRNA sequencing--Illumina MiSeq</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Estrogen metabolites</measure>
    <time_frame>At baseline (day 0) and 30 days after estrogen suppression, with and without dietary flaxseed 30 days before estrogen suppression and during the 30 days of estrogen suppression</time_frame>
    <description>estrogen metabolites (parent:metabolite ratio) in urine and plasma</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Menopause</condition>
  <arm_group>
    <arm_group_label>Estrogen suppression no flax</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Control subjects will not consume flaxseed, but will receive GnRH suppression</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Estrogen suppression with flax</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Flax subjects will consume flaxseed for 2 months in addition to GnRH suppression</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Flaxseed</intervention_name>
    <description>2 months of dietary flaxseed supplementation</description>
    <arm_group_label>Estrogen suppression with flax</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Estrogen suppression</intervention_name>
    <description>30 days GnRH agonist treatment</description>
    <arm_group_label>Estrogen suppression no flax</arm_group_label>
    <arm_group_label>Estrogen suppression with flax</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy premenopausal women (20-40 years)

          -  normal to overweight (22-29.9 kg/m2)

          -  normally menstruating (25-35 day cycles)

          -  not have used estrogen-based contraception for &gt;6 months.

          -  sedentary to moderately active (exercise ≤120 min week−1)

          -  must not be taking phytoestrogenic dietary supplements, or lipid- or glucose- lowering
             medications.

        Exclusion Criteria:

          -  smoking

          -  pregnancy or breastfeeding

          -  Hormonal contraceptive use (past 6 mo.)

          -  Women with contraindications to GnRHAG:

          -  History of fragility fracture

          -  Low BMD (i.e., proximal femur or lumbar spine z scores &lt; -2.0)

          -  Abnormal vaginal bleeding

          -  History of breast cancer or other estrogen-dependent neoplasms

          -  History of venous thromboembolic events

          -  Hypersensitivity to leuprolide acetate or benzyl alcohol (the vehicle for injection of
             leuprolide acetate)

          -  Evidence for depressive symptoms (Score ≥ 18 on the Beck Depression Inventory, BDI)

          -  Moderate or severe renal impairment defined as a calculated creatinine clearance &lt;50
             mL/min based on the equation of Cockcroft and Gault91

          -  Chronic hepatobiliary disease, conservatively defined as liver function tests (AST,
             ALT, alkaline phosphatase, Total Bilirubin) &gt;1.5 times the upper limit of normal (if
             such values are obtained on initial screening and thought to be transient in nature,
             repeated testing will be allowed)

          -  antibiotic or probiotic use within 2 months of sample collection
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kimberly Cox-york, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Colorado State University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kimberly Cox-york, PhD</last_name>
    <phone>9703977148</phone>
    <email>kimberly.cox-york@colostate.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tiffany Weir, PhD</last_name>
    <phone>9704914631</phone>
    <email>tiffany.weir@colostate.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Colorado State University</name>
      <address>
        <city>Fort Collins</city>
        <state>Colorado</state>
        <zip>80523</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kimberly Cox-York, PhD</last_name>
      <phone>970-491-3466</phone>
      <email>kimberly.cox-york@colostate.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 7, 2017</study_first_submitted>
  <study_first_submitted_qc>June 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 9, 2017</study_first_posted>
  <last_update_submitted>March 5, 2018</last_update_submitted>
  <last_update_submitted_qc>March 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Colorado State University</investigator_affiliation>
    <investigator_full_name>Kimberly Cox-York</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estrogens</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

